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Studies suggest that P. gingivalis functions as a keystone pathogen and interacts 
with primary colonizers in the supragingival biofilm such as S. gordonii. This 
interaction contributes to the initial colonization of the oral cavity by P. gingivalis 
and thus represents a potential target for therapeutic intervention. We have 
identified a peptide (BAR) derived from the streptococcal SspB protein that 
functions to inhibit P. gingivalis adherence to S. gordonii. In addition, we showed 
that nanoparticles (NPs) functionalized with BAR inhibit this interaction more 
potently than free soluble peptide, possibly by promoting interaction with P. 
gingivalis at higher valency than free peptide and increasing the avidity of the 
interaction. Two approaches were used to assess the valency of BAR- P. 
gingivalis interaction. First NPs were conjugated with various defined amounts of 
BAR. The resulting NPs were tested for inhibition of P. gingivalis adherence 
using a two-species biofilm model and the results were compared with inhibition 
by free peptide. Nanoparticle preparations were synthesized in the presence of 
 vi 
increasing amounts of fluorescently labeled or unlabeled BAR. We found that 
peptide bound to nanoparticles increased in a dose dependent manner ranging 
from 1.20 µg BAR/mg of NPs to 5.87 µg BAR/mg of NPs. We tested them for 
inhibition in the biofilm assay. We observed dose-dependent efficacy based on 
the amount of BAR peptide on the nanoparticle surface. Valency of BAR peptide 
directly correlated to increased inhibition. Second, inhibition of adherence was 
also determined using BAR-antibody fusion proteins in dimer and tetramer form.  
Peptide-antibody fusions were produced using a plant based production platform 
and tested as above. We designed nucleic acid constructs that encoded BAR-
antibody fusion proteins containing two or four molar equivalents of BAR. The 
fusion protein containing two equivalents of BAR was successfully expressed 
whereas the protein containing 4 BAR equivalents appeared to be toxic to cells 
expressing the protein. The fusion protein containing two BAR molecules showed 
a dose-dependent increase in the percent inhibition as the amount of the BAR 
peptide increased However, the Ab-BAR fusion peptide was not more potent 
than soluble BAR peptide. Increasing the valency of the BAR-P. gingivalis 
interaction may pave the way for development of more potent therapeutics that 
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Periodontitis is one of the most ubiquitous diseases and is characterized by the 
destruction of connective tissue and dental bone support following an 
inflammatory host response secondary to infection by periodontal bacteria 
(AlJehani, 2014). It is the most common disease of the oral cavity, affecting soft 
and hard structures that support the teeth, and has many clinical outcomes 
including loss of attachment, bone loss and eventually tooth loss (Albandar, 
2011; Dhadse et al, 2010). Periodontitis is second only to dental caries as a 
cause of tooth loss among adults in developed countries (Gautam et al., 2011). A 
study entitled Prevalence of Periodontitis in Adults in the United States: 2009 and 
2010 estimates that 47.2 percent of the American adults or 64.7 million 
Americans have mild, moderate or severe periodontitis (Eke et al., 2015). In 
adults, 65 years and older, the prevalence rate increases to 70.1 percent ( Eke et 
al., 2015). Other studies have demonstrated that mild forms of periodontitis affect 
75% of adults in the United States and more severe forms affect 20 to 30% of 
adults (Dhadse, et al, 2010). A study conducted combined the data from the
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 2009 to 2010 and 2011 to 2012 cycles of the National Health and Nutrition 
Examination Survey (NHANES). It concluded high prevalence of periodontitis in 
US adults aged ≥30 years, with almost fifty-percent affected (Eke et al., 2015). In 
the early stage of periodontitis, termed gingivitis, gums become swollen and red 
due to inflammation, which is the body's natural response to the presence of 
harmful bacteria. The colonization of bacteria in the supragingival area initiates 
an inflammatory response which leads to periodontitis (Brogden & Guthmiller, 
2002; Dickinson et al., 2011). Currently, treatments like removal of dental plaque, 
antibiotic therapy or gingival surgery (if required) may help to cure periodontitis. 
No therapeutic method has been devised to actually prevent the colonization of 
bacteria, thereby, preventing biofilm formation. 
 
Biofilm 
A biofilm is a structured community of micro-organisms that is adhered to a 
surface and enclosed in a self-generated matrix (consisting of carbohydrate 
polymers, proteins, and DNA) (Donlan, 2002). Microbial biofilms are known to 
cause a number of infectious diseases in humans, a few of which include 
tonsillitis, dental disease, urinary tract infections and endocarditis (Bjarnsholt, 
2013). Dental plaque is a complex oral multispecies biofilm that adheres to 
the teeth and consists of many species of both fungal and bacterial cells. 
According to World Health Organization, it is a specific but highly variable 
structural entity resulting from sequential colonization and growth of 
microorganisms on the surfaces of teeth and/or restorations (Rosan & Lamont, 
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2000). The biofilm consists of microorganisms of various species embedded in 
an extracellular matrix composed of bacterial metabolic products and substances 
from serum, saliva and blood. This accumulation of microorganisms subjects the 
teeth and gingival tissues to high concentrations of bacterial metabolites, often 
resulting in gingivitis and eventually periodontitis. Therefore, understanding the 
development of dental plaque and the corresponding etiology of periodontitis 
would help to develop therapeutics to prevent or cure periodontitis. 
 
Development of Dental Plaque 
The formation of biofilms occurs in a multistep progression (O'Toole et al, 2000). 
Obtaining a better understanding of the mechanisms of bacterial attachment and 
co-adhesion could lead to strategies to control or influence the pattern of biofilm 
formation. Distinct stages in plaque formation include the following stages 
depicted in Figure 1 (Chandki et al, 2011; Dickinson et al., 2011;  Marsh, 2006) 
 
Figure 1: Stages in biofilm formation. * adapted from wikipedia.org/wiki/File:Biofilm.jpg 
 
Plaque formation begins with the formation of the acquired pellicle (Diaz et al., 
2006). The pellicle is a thin coating of salivary proteins that adheres to the tooth 
 4 
surface within minutes after tooth eruption or cleaning (Armstrong, 1968). The 
pellicle is composed of albumin, glycoproteins, acidic proline-rich proteins, 
mucins, cell debris, amylase, lysozyme and sialic acid (Lindh et al, 2014). The 
pellicle provides a sticky base to support further microbial colonization (Lindh et 
al., 2014). Acidic phosphoproteins and proline-rich proteins mediate initial 
interactions with primary colonizing organisms, which are comprised largely of 
Gram-positive cocci, including streptococcal species (Marsh, 1994;  Marsh, 
2006). 
After pellicle formation, reversible adhesion contributes to the beginning of 
bacterial cell attachment (Garrett et al, 2008). Reversible adhesion involves weak 
long-range physicochemical interactions between the cell surface and the 
pellicle, which can lead to stronger adhesin-receptor mediated attachment 
(Garrett et al., 2008). Reversible adhesion is initiated with a single cell adhering 
to the surface from a ‘planktonic’ state, in which the bacteria are freely floating in 
the solution that bathes the oral cavity (Garrett et al., 2008).  This change from 
the ‘planktonic’ state is usually associated with the change in the expression of 
genes and also the phenotype leading to the adaptation of bacterial cell lifestyle 
from the planktonic environment to the environment on the tooth surface. 
After reversible adhesion, the cells start to proliferate and form microcolonies.  
This process may increase the diversity of the biofilm through co-adhesion 
between different species (Grenier, 1992; Kinder & Holt, 1989; Kolenbrander & 
Andersen, 1989). This results in the attachment of secondary colonizers to 
already adhered cells. Co-adhesion is driven by specific receptor-ligand 
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interactions that allow new bacterial colonizers to adhere to the previously 
attached cells and results in increased complexity of the microbial community 
(Grenier, 1992; Kinder & Holt, 1989; Kolenbrander & Andersen, 1989).  
At this stage, the microcolonies begin to produce an extracellular matrix 
comprised of extracellular carbohydrates and genomic DNA. The microcolonies 
continue to proliferate and develop into ‘mature biofilms’ that are characterized 
by vertical growth on the solid surface. The mature biofilm is a complex structure 
comprised of towering microcolonies interspersed with fluid filled channels, which 
provide nutrients and oxygen that are required for normal bacterial growth.  The 
channels are also conduits that facilitate the outward movement of bacterial 
metabolites, waste products, and enzymes. 
This biofilm life cycle is completed by the release of the bacterial cells back into 
the ‘planktonic’ state either by an ‘active’ or ‘passive’ process, known as 
detachment. In the active process, the cell itself may produce enzymes that 
cleave the matrix, reducing the integrity of the matrix and facilitating the release 
of cells.   Alternatively, cells in the biofilm may stop production of enzymes that 
produce the matrix. Thus the biofilm may become exposed and disintegrates.  In 
addition, ‘passive’ processes may also lead to the release of bacterial cells into a 
free floating state, which can then recolonize a new surface. For example, the 
physical abrasion of the tongue against the tooth may facilitate biofilm removal. 
During the process of biofilm formation, quorum sensing and other signal 
transduction pathways play an important role in biofilm growth and maturation. 
For example, the process by which bacterial cells adhere and interact with a  
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surface can initiate new genetic programs, allowing the microorganism to survive 
in the new environment (Blango & Mulvey, 2009). This is called ‘contact-
dependent signaling’. Contact dependent signaling can also occur between two 
different organisms. This interspecies adherence can stimulate new genetic 
programs that allow cells to alter their genetic profiles to enhance viability in the 
microbial community (Blango & Mulvey, 2009).  
 
Significance of Etiology of Periodontitis 
Some of the bacteria that contribute to the oral microbiotic community include 
Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola 
(Suzuki et al, 2013). These species are considered ‘periodontopathogens’, and 
are classified as ‘red’ complex oral bacteria that have a strong association with 
each other and with diseased sites in chronic adult periodontitis (Darveau et al, 
2012; Suzuki et al., 2013). Two main hypotheses may explain the role of plaque 
bacteria in a diseased individual. The “Specific Plaque Hypothesis” asserts that 
only specific species are involved in causation of disease, even if present in low 
abundance (Hajishengallis, 2014; Hajishengallis & Lamont, 2012; Loesche, 1992; 
Rosier et al, 2014). One of the ‘red complex’ bacteria, P. gingivalis, has been 
described to function as a keystone pathogen (Hajishengallis & Lamont, 2012; 
Rocas et al., 2001; Rosier et al., 2014). It disrupts host-microbe homeostasis in 
the oral cavity leading to dysbiosis even in low abundance, and is thus strongly 
associated with adult periodontitis (Hajishengallis & Lamont, 2012). Given this 
impact at low abundance, it is believed that P. gingivalis alters the host response 
 7
and induces changes in microbial biofilm populations, prompting uncontrolled 
inflammation and tissue damage (Darveau, 2010; Hajishengallis & Lamont, 2012; 
Loesche, 1992). However, this hypothesis cannot completely explain the 
absence of presumed pathogens in some diseased individuals or the presence of 
these pathogenic organisms in healthy patients (Darveau, 2010). Contrary to this, 
the "Non-Specific Plaque Hypothesis" proposes that periodontitis is a result of 
the overall interaction of the plaque microflora with the host (Hajishengallis & 
Lamont, 2012; Rosier et al., 2014). It is well established that plaque-mediated 
diseases have a multi-factorial etiology and a variety of organisms are involved in 
its progression (Hajishengallis & Lamont, 2012; Rosier et al., 2014). Considering 
both theories, a modified hypothesis has been proposed suggesting that changes 
in environmental factors lead to a shift in the resident microflora resulting in 
microbial dysbiosis (Rosier et al., 2014). This modified hypothesis supports the 
occurrence of potentially pathogenic species as minor members of the resident 
plaque microflora (Rosier et al., 2014). Certain low-abundance microbial 
pathogens can cause inflammatory disease by interfering with the host immune 
system and remodeling the microbiota (Hajishengallis & Lamont, 2012; Rosier et 
al., 2014). In healthy individuals, these organisms would be weakly competitive 
and significantly suppressed by intermicrobial antagonism (Hajishengallis & 
Lamont, 2012; Rosier et al., 2014). As such, they would comprise only a small 
percentage of the plaque microflora and would have limited clinical significance 
(Rosier et al., 2014).  
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P. gingivalis and its interaction pattern 
 Apart from being considered a keystone pathogen, P. gingivalis has long been 
associated with periodontitis, has a well-characterized population structure, and 
demonstrates the “easiest” growth and genetic manipulation of the three ‘red 
complex’ bacteria (Rocas et al., 2001). Due to these factors, P. gingivalis has 
garnered much attention and has been well-studied (Curtis et al., 2011; Darveau 
et al., 2012; Lamont & Jenkinson, 1998). P. gingivalis is a pathogen whose 
primary niche is in the anaerobic environment of subgingival dental plaque; 
however, initial colonization occurs on supragingival surfaces that already 
support robust biofilm communities in oral cavity (Daep et al., 2006). Studies 
suggest that biofilm formation occurs subsequent to initial adherence of P. 
gingivalis to S. gordonii cells deposited on the salivary pellicle (Cook et al., 
1998). The interaction between P. gingivalis and S. gordonii is one of the many 
critical interactions which promote biofilm formation. Targeting this particular 
interaction may inhibit the biofilm formation more effectively, if not completely. 
The commensal species S. gordonii provide an attachment substrate for 
colonization and biofilm accretion by the potential pathogen, P. gingivalis (Cook 
et al., 1998). Due to this favorable interaction, P. gingivalis, has been shown to 
specifically adhere to primary colonizing bacteria such as S. gordonii (Park et al., 
2005). Considering this, the initial colonizing mechanism of P. gingivalis is a 
primary target to inhibit biofilm formation with rationally designed therapeutics 




P. gingivalis is  a leading pathogen implicated in chronic adult periodontitis 
(Koziel et al., 2014). Previous studies have shown that P. gingivalis adheres to S. 
gordonii through the interaction of the minor fimbrial antigen, Mfa1, with a specific 
region of the streptococcal SspB polypeptide which has been designated BAR 
(SspB Adhering Region) (Chung et al., 2000; Daep et al., 2006; Daep et al., 
2008; Demuth et al., 2001; Lamont et al., 2002). It has been shown that a 
synthetic peptide comprising the BAR sequence potently inhibits P. gingivalis 
adherence to S. gordonii (IC50=1.3 µM) (Daep et al., 2006; Daep et al., 2008; 
Daep et al., 2011).  Moreover, BAR peptide significantly reduced P. gingivalis 
virulence in mice that harbor S. gordonii when administered simultaneously with 
P. gingivalis cells (Daep et al., 2011). However, the effects of BAR administration 
demonstrated transient effects, and exhibited weaker potency against pre-
existing or more complex biofilms.  In more complex biofilms, the IC50 increased 
to 3.6 µM and an exposure time of more than 60 minutes was required to achieve 
equivalent effects as achieved in two species biofilms (Demuth, unpublished). 
These limitations to clinical translation spurred the need to develop novel 
approaches to deliver BAR peptide at higher localized concentrations to increase 
efficacy. Our recent studies suggested that poly (lactic-co-glycolic acid) (PLGA) 
nanoparticles (NPs) that are surface-functionalized with BAR inhibit P. gingivalis 
and S. gordonii interactions more potently than free soluble peptide (Steinbach-
Rankins and Demuth, unpublished).  
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Advantages of Nanoparticles as advanced therapeutics 
Nanoparticles are being studied extensively as a delivery method for 
antimicrobials for various diseases (De Jong & Borm, 2008; McMillan, Batrakova 
et al., 2011; Singh & Lillard, 2009). They offer many advantages over 
conventional therapeutic approaches that deliver free antimicrobials via oral, 
submucosal, or localized delivery routes (Gelperina et al., 2005; Ikuma et al., 
2015; Singh & Lillard, 2009). First, due to their small size, NPs can penetrate 
barriers to deliver higher concentrations of active agents at target sites, providing 
increased efficacy (Mudshinge et al. , 2011; Singh & Lillard, 2009). Second, NPs 
can be tailored to recognize specific cell types simply by altering their surface-
chemistry (Mudshinge et al., 2011; Singh & Lillard, 2009). Moreover, NPs allow 
for prolonged delivery of drugs which helps to increase the efficacy of the drugs 
for increased durations under often adverse physiological conditions in vivo 
(Hong et al., 2007; Puglia et al., 2008; Singh & Lillard, 2009). Also, NPs may 
promote multivalent binding which can act to increase the potency of active 
agents (Hong et al., 2007). In addition to this, NPs promote the stability of active 
agents in vivo, by protecting the agent from degradation. Apart from these 
advantages, NPs can carry a diversity of hydrophilic and hydrophobic active 
agents (e.g. drugs, proteins, peptides, genes, etc.) that can be co-incorporated in 
the NP matrix and can be administered orally, locally and intravenously (Mody et 




 NPs have been developed using a variety of materials including metals, 
ceramics and polymers (Abiodun-Solanke et al., 2014; Adeyemi & Sulaiman, 
2015; De Jong & Borm, 2008; Wang & Wang, 2014). Silver NPs have been 
widely used in dentistry to fabricate new materials like cements or resins (Arvizo 
et al., 2012; Batra & Miglani; Ge et al., 2014; Batra et al. 2016). Magnetic NPs 
like magnetite and maghemite, which are comprised of iron oxide, have been 
actively studied for cancer and gene therapy applications (Gobbo et al., 2015; 
Herranz et al., 2011; Batra et al. 2016, unpublished). Copper, zinc, titanium 
dioxide and quaternary ammonia NPs have demonstrated antimicrobial activity 
and their hydrophobic nature and surface charge add to their antimicrobial 
activity (Batra et al. 2016, unpublished). Many of the metal-based NPs have 
imparted antimicrobial properties that have proven beneficial to oral health by 
improving the interaction of therapeutics with bacterial biofilms and inhibiting the 
biofilm formation (Allaker, 2010; Senior et al., 2012; Sirelkhatim et al., 2015; 
Batra et al., 2016). The proposed mechanism of these antibacterial activities is 
believed to arise from an electrostatic attraction of positively-charged NPs with 
the negative charge of the bacterial cell membrane (Palza, 2015; Singh & Lillard, 
2009). Other novel systems using silica NPs and nitric oxide NPs are being 
studied for to prevent biofilms as well (Kafshgari et al., 2014; Batra et al. 2016). 
However, despite these attributes, there have been several concerns regarding 
the toxicity associated with the metallic NPs  and their accumulation in various 
tissues and organs (Niazi & Gu, 2009). To avert the toxicity associated with metal 
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NPs, polymeric NPs have the potential to offer a safer and more biocompatible 
delivery method.  
 
Polymeric NPs 
Polymeric NPs have demonstrated biocompatibility and flexible tuning of physical 
properties enabling the drug release and dosage profiles. There are many types 
of polymeric NPs including poly (lactic acid) (PLA), poly(ε-caprolactone) (PCL), 
polyethyleneimine, poly (lactic-co-glycolic acid) (PLGA) and poly (glycolic acid) 
(PGA). These polymers have been extensively used to prevent oral biofilms due 
to their biodegradability and biocompatibility (Allaker, 2010; Wang et al., 2016). 
Furthermore, polymeric NPs comprised of PLA and PGA, have the ability to 
degrade into relatively inert metabolic by-products, enabling safe and non-toxic 
delivery of associated cargo.  
 
PLGA Nanoparticles 
 PLGA NPs have been FDA-approved for use in human therapy which is one of 
the primary reasons for extensive research using these particles (Makadia & 
Siegel, 2011). PLGA can deliver hydrophilic and hydrophobic small molecules as 
well as larger macromolecules due to its well described formulation protocols 
(Martin-Banderas et al., 2013). PLGA NPs are being tested for use in 
photodynamic therapy, which when introduced into a bacterial cell, release 
singlet oxygen and free radicals to destroy bacterial cells (Li & Huh, 2014). In 
other work, PLGA NPs that encapsulate methylene blue have demonstrated 
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efficacy against Gram-positive as well as Gram-negative bacteria associated with 
endodontic as well as periodontal infections (Klepac-Ceraj et al., 2011). In 
addition to the attributes that encapsulation provides, PLGA NPs can be surface-
modified to provide specific targeting and enhanced therapeutic outcomes 
(Makadia & Siegel, 2011). Advanced studies are still being done to impart 
knowledge about the basic functionality of the PLGA NPs with various peptide 
modifications, yet these are considered to be promising antimicrobials delivery 
vehicles relative to less specifically-acting conventional therapeutics (Makadia & 
Siegel, 2011).  
Our preliminary studies have suggested that PLGA NPs that are surface-
modified with BAR peptide increase the effectiveness of peptide-mediated 
inhibition of P. gingivalis-S. gordonii adherence. A possible mechanism by which 
these NPs enhance the potency is by promoting a multivalent binding interface to 
increase the avidity of BAR with P. gingivalis, or by delivering BAR at a higher 
localized concentration to P. gingivalis. In fact, many studies have demonstrated 
that multivalent interactions are more efficacious in increasing the avidity of 
peptides relative to monovalent interactions (Figure 2) ( Wang et al., 2016). In 
one study, a specific special multivalent effect was observed for polymeric NPs 
displaying galactan, resulting in a significant increase in binding, relative to free 
glycan (Bonduelle et al., 2016). In another study, multivalent targeting approach 
was shown to have the potential to amplify AT1R (Angiotensin 1 Receptor) 
blockade in the eye and concomitantly deliver a therapeutic payload into ocular 
lesions choroidal vasculature (Hennig et al., 2015). Similar to these studies, we 
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expect that the increase in potency of the surface modified NPs may be due to 
the increase in the valency. 
 
 
Figure 2 Comparison of monovalent and multivalent interactions. Multivalent interactions 
are considerably stronger than the individual bonding of a corresponding number of 
monovalent ligands to a multivalent receptor and are often used in biological systems. 
Adapted from Prof. Dr. Rainer Haag research topics. 
 
 
Drug delivery by binding to Immunoglobulins 
Therapeutic drugs and proteins often suffer from short half-life; mainly due to 
their small size or rapid clearance by enzymes. Genetic modification of these 
drugs or proteins employing various techniques can improve the 
pharmacokinetics by prolonging the half-life by either preventing excretion or 
degradation in the body. Like albumin, certain immunoglobulins IgG1, IgG2 and 
IgG4 also bind to the FcRn (neonatal Fc receptor) and thus have a long half-life 
(Strohl, 2015). Similar to the fusion of albumin binding moieties, IgG binding 
domains (IgBDs) can be fused to therapeutic proteins. Studies have shown 
 15 
different IgBDs have different affinity for serum immunoglobulins resulting in 
different half-lives. The longest half-life of 21 to 23 hours has been seen with the 
C3 domain from Streptococcal Protein G (SPG-C3) when fused to recombinant 
antibodies (Kontermann, 2016). 
 
Various types of Fusion Proteins (Genetic fusion to Immunoglobulins) 
In addition to evaluating multivalent NPs for the delivery of BAR peptide, we 
designed antibody-fused peptides to evaluate the effect of BAR valency. The 
antibodies acted as another carrier for the peptide. Relative to NPs, BAR fusion 
proteins offer the attributes of smaller size and definitive conjugation, allowing us 
to easily assess the impact of valency on increased binding and corresponding 
potency. This fusion protein allows us to begin to assess the degree of valency 
that is required to increase potency of the peptide to inhibit biofilms. Fusion of 
proteins to the Fc region of IgG 1, 2 and 4 will impart longer half-lives due to 
binding of FcRn (neonatal Fc Receptor) to Fc region and FcRn mediated 
recycling. Examples of Fc fusion proteins include TNF receptor 2 (etanercept), 
VEGF (vascular endothelial growth factor) receptor (aflibercept), IL-1 receptor 
(rilonacept), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (abatacept, 
belatacept) and others (Strohl, 2015). Etanercept was the first approved Fc 
fusion protein. Fc fusion is also used to extend the half-lives of biologically active 
proteins. Romiplostim, a thrombopoetin mimetic Peptide-Fc fusion protein is 
approved for treating immune thrombocytopenia (Kontermann, 2016) . Alprolix 
(Factor IX-Fc), a monomeric Fc fusion molecule, showed a terminal half-life of 
57-83 hours which was approximately three times more than the half-life of other 
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formulations of Factor IX (Strohl, 2015). These fusion proteins and various others 
like Dulaglutide (GLP-1-Fc fusion protein), Efraloctocog-α (Factor VIII fused to 
IgG1 Fc), Corifollitropin-α (FSH-CTP fusion) have been approved for marketing 
(Strohl, 2015). Broadly neutralizing monoclonal antibodies (bnMAbs) may offer 
powerful tools as topical microbicides (Hamorsky et al., 2013). However, this 
option is hampered due to expensive MAb bio manufacturing based on 
mammalian cell culture. To address this issue, a new production system for 
bnMAb VRC01 in Nicotiana benthamiana plants using a tobamovirus replicon 
vector was developed (Hamorsky et al., 2013). Also, the production of antibodies 
using the conventional IgG production is not very safe. This novel plant based 
production system is being used for our  experiments and  employs  a simple 
manufacturing process, as opposed to  the conventional system which utilizes 
two separate vectors for H and L chain (Hamorsky et al., 2013). This provides a 
more consistent and a stable production as it generated antibodies from a single 
polypeptide (Hamorsky et al., 2013). We will use an IgG antibody fused to the 
BAR peptide to test the inhibition of interaction between P. gingivalis and S. 
gordonii and compare it with the soluble BAR peptide. In addition to the small 
size of the Ab as compared with the NPs, another reason for us to use it in our 
experiments is because it would allow us to be able to compare the number of 
BAR molecules on the NPs of the lowest BAR concentration (8.9 µg/mg NPs) to 
the number of BAR molecules (2 or 4) on the BAR-Fc fusion. It would help us to 
determine whether or not there is a particular number of BAR molecules required 
to show an increase in potency. 
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CHAPTER 2 
HYPOTHESIS AND SPECIFIC AIMS 
 
Our overall HYPOTHESIS is that BAR-NPs may interact with P. gingivalis with 
higher valency than free soluble peptide, thereby increasing the avidity and 
potency of the interaction.  This hypothesis will be tested using two approaches.  
The first will utilize BAR-modified NPs which can be functionalized with a high 
peptide valency.  The second approach will examine BAR-antibody fusions with 
lower and more well-defined peptide valency. The Specific Aims are to: 
 
SPECIFIC AIMS 
1) Construct BAR-modified PLGA nanoparticles and determine whether NPs 
promote multivalent interaction with P. gingivalis.   
2) Construct BAR-antibody fusion proteins in dimer and tetramer forms and 
determine if they function as more potent inhibitors of P. gingivalis adherence 
relative to free peptide 
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CHAPTER 3 
MATERIALS AND METHODS 
 
Peptide Synthesis 
The peptide containing a covalently attached biotin at its N-terminus was 
synthesized by BioSynthesis, Inc. (Lewisville, TX) and was obtained with greater 
than 85% purity. The peptide is comprised of residues 1167 to 1193 of the SspB 
(Antigen I/II) protein sequence of S. gordonii. The BAR-Flc (Fluorescent BAR 
peptide) and unlabeled biotin BAR peptide used in this study, is shown in Table 
1. Both contain biotin (BTN) attached to the N-Terminus and were obtained in 
lyophilized form.  
 
Table 1 Sequence of BAR peptide. 
Peptide Name Peptide Sequence 
BAR-Flc ( BTN )-LEAAPK-Kflc-VQDLLKKANITVKGAFQLFS-
OH 
BAR ( BTN )-LEAAPKKVQDLLKKANITVKGAFQLFS-OH 
 
To determine the amount of BAR peptide on the NP surface, we used the 
fluorescent BAR peptide (BAR-Flc) which is synthesized by covalently attaching
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 6-carboxyfluorescein (Flc) to the epsilon amine of the lysine residue that is 
underlined in Table 1. 
 
Growth of Bacterial Strains 
P. gingivalis strain ATCC 33277 was grown in Trypticase soy broth (TSBY 
medium) (Difco) supplemented with 0.5% (w/v) yeast extract, 1 μg/ml (final 
concentration) menadione, and 5 μg/ml (final concentration) hemin. Twenty 
milliliters of media was reduced for 24 hours under anaerobic conditions 
consisting of 10% CO2, 10% H2, and 80% N2. Next, P. gingivalis was inoculated 
into the medium and grown for 48 hours at 37°C under anaerobic conditions. S. 
gordonii DL-1 was cultured aerobically without shaking in brain-heart infusion 
(BHI) broth supplemented with 1% yeast extract for 16 hours at 37°C. 
 
Avidin-Palmitic Acid Conjugation 
To obtain BAR-modified PLGA NPs, the NP surfaces were modified with avidin 
palmitate to subsequently attach biotinylated BAR. Avidin-palmitate was 
conjugated as described by Fahmy and Saltzman (Fahmy et al., 2005). Briefly, 
10 mg of avidin was dissolved in 1.2 ml of 2% sodium deoxycholate (NaDC) in 
phosphate buffered saline (PBS) warmed to 37 °C. Palmitic acid-NHS (PA-NHS, 
Sigma) was dissolved in 2% NaDC at 1 mg/ml and sonicated until well-mixed. 
Eight hundred microliters of the 1 mg/ml PA-NHS (PA-N-hydroxysuccinamide 
ester, Sigma) solution was added dropwise to the reaction vial, and reacted 
overnight at 37 °C. The following day, the reaction was dialyzed in 1200 ml of 
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0.15% NaDC in PBS heated to 37 °C with 3500 MWCO dialysis tubing to remove 
free PA-NHS. The solution was dialyzed overnight at 37 °C, and dialysis cassette 
contents were transferred to a storage vial and stored at 4 °C. Two milliliters of 
the above made PA-NHS solution was added dropwise to the reaction vial 
containing avidin, and reacted overnight at 37ºC. The following day, the reaction 
was dialyzed in 1.2L of 0.15% (w/v) NaDC in PBS. This dialysis sink solution was 
heated to 37ºC, and a 3500 molecular weight cut off (MWCO) dialysis tube was 
used to remove free PA-NHS. After overnight dialysis at 37ºC, complexed avidin-




Surface-modified avidin NPs were made using the oil-in-water (o/w) single 
emulsion technique. On the first day, two 100 mg PLGA NP batches were each 
dissolved in 2 ml DCM overnight. The next day, 2 ml of 5% (w/v) polyvinyl alcohol 
(PVA) was mixed with 2 ml of 5 mg/ml avidin-palmitate and vortexed slowly. 
PLGA-DCM solution was subsequently added dropwise to two tubes that 
contained the previously mixed PVA-Avidin-Palmitate (4 ml) while vortexed at 
slow speed, with subsequent ultrasonication (Figure 3). 
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Figure 3 Oil-in-water single emulsion technique. 
 
The DCM solvent was evaporated by adding the NP solution dropwise to 50 ml of 
0.3% PVA and mixed for 3 hours.  After evaporation, the solution was divided 
between six tubes and centrifuged at 13,000 rpm for 10 minutes at 4C to wash 
the NPs prior to peptide conjugation. The supernatant was discarded and the 
pellet was suspended in 10 ml PBS. Each of the four tubes was incubated with 1 
ml of BAR-Flc each at a different concentration for 1 hour. The concentrations 
used were 8.9, 17.8, 35.5, 71, 142 and 284 µg BAR/mg NPs, dissolved in 1 ml 
PBS, for a total of 10 ml reaction volume. After the reaction, NPs were 
transferred to centrifuge tubes, washed with 20 ml PBS and centrifuged again. 
The NPs were then suspended with 20 ml DI water and washed three times to 
remove unbound peptide. After three washes, the NPs were suspended in 5 ml 
of distilled water, transferred to a 10 ml cryotube, frozen in -80°C for 3 hours and 
subsequently lyophilized. All NPs were stored at -20ºC after synthesis. The 
surface-modified particles with unlabeled non-fluorescent BAR peptide were 
synthesized similarly.  
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Synthesis of BAR-Fc Fusion Protein 
 A gene fusion protein encoding the desired Ab fused to BAR was synthesized. A 
chimeric rabbit human monoclonal antibody sequence was used that was 
designed and constructed by Dr. Palmer’s team in the Owensboro Cancer 
Research Program. A BAR-Fc fusion dimer (Fc) (Figure 4) was constructed in 
which a signal peptide was fused to the BAR peptide, then fused to the IgG1 
hinge and Fc region. The signal peptide is a naturally occurring secretion signal 
that are meant to be transported out from the cells. Once it is secreted, the 
protein is easy to purify. The hinge serves as a flexible spacer between the two 
parts of the Fc fusion protein, allowing each part of the molecule to function 
independently. Utilizing these motifs, enabled alterations in the fusion protein 
valency. Human IgG1 displays high ADCC (Antibody-dependent cell-mediated 
toxicity) and CDC (Complement dependent toxicity), and is the most suitable for 
therapeutic use against pathogens and cancer cells.  
For the dimer molecule, each Fc protein has two BAR peptide molecules 
attached to it. In the case of the tetramer (Fc’) (Figure 5), the signal peptide fused 
to the BAR peptide was additionally fused to both the light chain and heavy chain 
in place of the rabbit VL and VH sequences, resulting in a valency of four 
peptides conjugated to each Fc’ molecule. 
The gene was delivered via the Tobamoviral vector into Nicotiana benthamiana 
leaves.  The leaf material, 5-7 days post-infiltration, was homogenized and the 
protein was extracted and purified.  Host kex2p protease was used for cleavage 




Figure 4: BAR-Fc fusion dimer (Fc) showing BAR peptide fused to IgG1 hinge and Fc 
region. Rice alpha amylase signal peptide (light blue), BAR peptide (light orange), 
Human IgG1 hinge + Fc (dark green) 
 
Figure 5 Fc’: BAR-Fc fusion tetramer having a full antibody molecule (Fc’) showing BAR 
peptide fused to both constant light and constant heavy chain in place of variable light and 
variable heavy chain. Rice alpha amylase signal peptide (light blue), BAR peptide (light 
orange), Constant light chain (light green), KP6 propeptide sequence (dark yellow), 






































To measure the amount of BAR peptide that was conjugated to the NP surface, a 
fluorescent binding assay was conducted. NPs were reacted with BAR-Flc as 
described above.  A 1 mg/ml solution of NPs in 1X PBS was made and one 
hundred microliters of the suspension was added to 96-well black microtiter 
plates in triplicate. The fluorescence was measured at excitation/emissions 
wavelengths of 485 nm/535 nm, and the background fluorescence was 
subtracted from the final fluorescence readings.  The level of BAR associated 
with the NP samples was determined by comparing fluorescence with a standard 
curve of BAR-Flc.  To obtain the standard curve of BAR-Flc, a serial dilution of 1 
mg/ml BAR-FLC stock was mixed with buffer to generate a range of peptide 
concentrations from 0.01 to 100 µg BAR peptide per ml.  
 
Dual Species Biofilm Assay 
Testing NP-BAR Inhibition  
Cultures of P. gingivalis and S. gordonii were obtained as previously described. 
S. gordonii DL-1 cells were harvested by centrifuging a 19 ml culture of S. 
gordonii at 5600 rpm for 15 min. One milliliter was used to measure the initial 
O.D. (optical density) of cells. The supernatant was discarded and the cell pellet 
was suspended in 1 ml of 1X PBS. S. gordonii was labeled with 40 μl of 5 mg/ml 
hexidium iodide (Molecular Probes, Eugene, OR) and incubated for 15 min at 
room temperature on a rocker platform protected from light. After incubation, the 
labeled samples were centrifuged at 10,000 rpm for 3 mins, the supernatant was 
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discarded, and the cells were suspended in 1 ml of 1X PBS. Following this, the 
O.D. was measured at 600 nm from twenty-fold diluted cultures of S. gordonii to 
determine cell count. For all experiments, the optical density of S. gordonii cells 
was adjusted to 0.8 for uniformity of the S. gordonii cell counts in each well. After 
adjusting the optical density, 1 ml of S. gordonii cells was added to each well of 
five 12-well culture plates containing a sterilized micro-coverslip. The cell culture 
plates were wrapped in aluminum foil to protect the labeled cells from light and 
placed on a rocker platform in the anaerobic chamber for 24 hours. 
P. gingivalis cultures used for biofilm formation were optimized using a similar 
approach. In short, 19 ml of P. gingivalis cells were centrifuged for 15 min at 
5600 rpm and 1 ml was used to measure the initial O.D. The supernatant was 
discarded and the cell pellet was suspended in 1 ml of pre-reduced 1X PBS. P. 
gingivalis cells were labeled with 40 μl of 4 mg/ml carboxyfluorescein–
succinylester (Molecular Probes). Cells were incubated with the fluorescent dye 
for 15 mins on a rocker platform and protected from light. Following incubation, 
cells were centrifuged at 10,000 rpm for 3 min and the supernatant was 
discarded to remove the unbound fluorescent dye. The pelleted cells were 
suspended in 1ml of pre-reduced 1X PBS. The optical density of P. gingivalis 
cells was adjusted to 0.4 for uniformity of the P. gingivalis cell counts in each 
well.  
For biofilm inhibition experiments, BAR-NPs, soluble BAR or avidin-only NPs 
were pre-incubated with labeled P. gingivalis at 25°C for 30 min before 
transferring to the appropriate wells. The NPs that were surface-modified with 
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unlabeled BAR peptide were used for these experiments. For each batch of NPs 
that were synthesized, using input concentrations of BAR of 71 µg BAR/mg NPs, 
35.5 µg BAR/mg NPs, 17.8 µg BAR/mg NPs, or 8.9 µg BAR/mg NPs, five 
different concentrations of BAR (0.3 µM, 0.7 µM, 1.3 µM, 2.0 µM, 2.5 µM) were 
tested for biofilm inhibition. After calculating the amount of NPs required to 
deliver the desired level of BAR peptide, one milliliter of each of these solutions 
was added in triplicate to the culture plates. Molar equivalents of free BAR 
peptide (0.3 µM, 0.7 µM, 1.3 µM, 2.0 µM, 2.5 µM) were also tested.  Controls 
comprised treating cells with PBS alone or with avidin-only NPs in triplicate.  The 
cell culture plates were covered with aluminum foil and incubated for 18-24 hours 
in an anaerobic chamber. 
Following incubation, the supernatant was removed from the wells of the cell 
culture plates and the cells were washed with pre-reduced 1X PBS to remove 
non-adherent bacterial cells. The cells were subsequently fixed with 4% (w/v) 
paraformaldehyde, excess paraformaldehyde was removed, and the cells were 
washed with pre-reduced 1X PBS. After washing, the coverslips were mounted 
on a glass slide using Prolong Gold anti-fade reagent and viewed using confocal 
laser scanning microscopy. 
 
Testing BAR-Fc Fusion Inhibition  
Biofilm inhibition by the purified BAR-Fc fusion protein was conducted similarly 
as described above. Three different concentrations of the BAR-Fc fusion protein 
were tested; 1 µM, 0.5 µM, and 0.25 µM, corresponding to 2.0 µM, 1.0 µM and 
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0.5 µM equivalents of BAR, respectively, since each fusion protein contained two 
molecules of BAR. Free BAR-peptide (unlabeled) at concentrations of 2.0 µM, 
1.0 µM and 0.5 µM were tested.  Control reactions consisted of treating cells with 
PBS alone or with antibody that did not contain BAR.  
 
Confocal Microscopy  
P. gingivalis-S. gordonii biofilms were visualized using a Leica Microsystems 
confocal laser scanning microscope (TCS SP8) and the Leica Application Suite X 
software. The slides were viewed using an argon laser for visualization of FITC-
labeled P. gingivalis and the HeNe-G laser to visualize hexidium iodide-labeled 
streptococci. P. gingivalis binding was determined from randomly chosen frames 
using Leica Application Suite X Software. Z-stack images of the biofilms were 
obtained using a z-step size of 0.7 μM and were constructed and analyzed using 
the Volocity image analysis software. 
 
Image Analysis 
After obtaining biofilm images using confocal microscopy, the resulting z-stack 
images were processed and reconstructed into 3D images using the Volocity 
software. Images were imported into Volocity as multiple Tiff-files. Uniform filters 
were used to remove noise from the images and were further analyzed to 
quantify the extent of P. gingivalis binding. The image brightness and contrast 
was adjusted equally for all frames, and a snapshot of the image was captured. 
Next, the ratio of green to red fluorescence was determined. Each peptide 
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concentration was analyzed in triplicate and 3 independent frames were 
measured for each well. The mean and variation (SD) between samples was 
determined using ANOVA. The variation was considered statistically significant 


















Surface Modification Efficacy of PLGA NPs with BAR Peptide 
A fluorescence assay was used to determine the amount of BAR peptide that 
was bound to the surface of the NPs.  Avidin-NPs were titrated with BAR peptide 
at six different concentrations; 8.9, 17.8, 35.5, 71,142 and 284 µg BAR/mg NPs. 
Previous experiments showed that a concentration of 142 µg BAR/mg NPs was 
required to saturate the available avidin binding sites. However, in those 
experiments 2 ml of 5 mg/ml avidin was used to modify 50 mg PLGA NPs during 
synthesis. In the current experiments, 2 ml of 5 mg/ml avidin was used to modify 
100mg PLGA NPs, resulting in half the modification density (per mg NP) used in 
previous experiments. To measure the degree of modification, NPs were 
incubated with various concentrations of BAR-Flc for 1 hour, washed, frozen, and 
lyophilized.  Fluorescence was measured as previously described. We observed 
that the incorporation of BAR-Flc was directly related to the concentration of 
BAR-Flc added. A standard curve (Figure 6) of soluble BAR-Flc was used to 
quantify the output concentration of BAR. 
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Figure 6 Standard Curve for free BAR peptide showing fluorescence at increasing BAR 
amounts. This graph was used to calculate the BAR Flc output concentration for the 




Figure 7 Saturation curve for fluorescently labelled BAR. The input concentration of 
BAR was varied and resulted in a dose-dependent amount of BAR conjugated to the NP 
surface ranging from 1.48 to 5.87 µg BAR/mg NPs.  We observed that above 71 µg 
BAR/ mg NP (input concentration), the avidin sites on the NP surface were saturated 
resulting in no additional conjugation to the NP surface. 













































As shown in Figure 7, an input concentration of 71 µg/mg NPs resulted in 
saturation, indicating that all available avidin binding sites were bound by biotin-
BAR peptide. Beyond this input concentration, additional peptide was not 
conjugated to the NP surface.  
 
Table 2 Correlation between the input concentration of BAR-FLC peptide and quantity of 
BAR-FLC on the NP surface. Increasing amounts of BAR peptide resulted in increased 
amounts of conjugated BAR. However, above 71 ug BAR/mg NP, the NP surface was 
saturated as seen in Figure 7. 
Sample 
[Input: Quantity of BAR-
Flc peptide (ug) reacted 




Flc peptide (ug) 
bound to 
surface of NPs 
(mg), ug/mg] 
A 284 5.87±0.48 
B 142 5.69±0.95 
C 71 5.66±0.20 
D 35.5 2.90±0.16 
E 17.8 1.48±0.17 
F 8.9 1.20±0.68 
 
Previous experiments showed incorporation of 1.5 nmol avidin per mg NP.  
Assuming 4 binding sites per avidin, the maximal payload of BAR is 6 nmol per 
mg NP (~22 g/mg NP).  According to Table 2, after reacting the NP surface with 
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71, 142, and 284 µg BAR/mg NPs, the NP surface was saturated with BAR 
peptide, and bound approximately 5.7 g BAR per mg NP.  This suggests that 
26% of the avidin binding sites are available for interaction with BAR.   
 
Biofilm Inhibition Assay with BAR-NPs 
The biofilm inhibition and fluorescence binding assays were performed in parallel 
to minimize experimental errors. As previously discussed, different 
concentrations of BAR-NPs were evaluated to determine the effect of peptide 
valency on P. gingivalis and S. gordonii inhibition. Streptococcal cells were 
immobilized and P. gingivalis was incubated with S. gordonii for 18-24 hours. The 
biofilms were visualized using confocal microscopy and the percent inhibition 
was calculated by determining the ratio of S. gordonii to P. gingivalis cells using 
Volocity. Previous studies showed that the IC50 (50% inhibitory concentration) of 
soluble BAR was 1.3 µM; therefore, a range of BAR molar equivalents ranging 
from 0.3 - 2.5µM was tested for each formulation of BAR-NPs (containing 
payloads of 1.20, 1.48, 2.90 and 5.66 µg BAR/mg NP; see Table 2). For control 
reactions, P. gingivalis was treated with defined concentrations of soluble BAR 
(1.3, 2.0, and 2.5M) or avidin-NPs alone. P. gingivalis was also incubated with 
S. gordonii in the presence of buffer alone. The corresponding biofilm images are 
shown in Figures 8 and 9.
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Figure 8: BAR-NP inhibition of P. gingivalis (green cells) adherence to S. gordonii (red 
cells). Biofilms were visualized by confocal microscopy and image stacks were 
assembled using Volocity image analysis software. The concentrations indicated on the 
images represent BAR peptide equivalents on the NP surface. As the surface density of 
BAR on the NP surface decreases (left-to-right), a decrease in biofilm inhibition is 
observed, indicated by the increased presence of P. gingivalis cells (green). Similarly, as 
the molar equivalent of BAR peptide delivered by each NP formulation is decreased 
(top-to-bottom), we observe a decrease in biofilm inhibition indicated by the increased 
presence of P. gingivalis cells (green). This figure displays molar equivalents of BAR 






Figure 9: BAR-NP inhibition of P. gingivalis (green cells) adherence to S. gordonii (red 
cells). Biofilms were visualized by confocal microscopy and image stacks were 
assembled using Volocity image analysis software. The concentrations indicated on the 
images represent BAR peptide equivalents on the NP surface. As the surface density of 
BAR on the NP surface decreases (left-to-right), a decrease in biofilm inhibition is 
observed, indicated by the increased presence of P. gingivalis cells (green). Similarly, as 
the molar equivalent of BAR peptide delivered by each NP formulation is decreased 
(top-to-bottom), we observe a decrease in biofilm inhibition indicated by the increased 
presence of P. gingivalis cells (green).  This figure displays molar equivalents of BAR 
ranging from 1.3 to 0.3 µM. 
 
 
Robust formation of P. gingivalis/S. gordonii biofilms occurred in the PBS and 
avidin-NP control reactions, whereas significant inhibition of biofilm formation 
was seen when cells were incubated with the BAR-NP preparations.  This 
indicates that NPs without BAR have no effect of P. gingivalis adherence to 
streptococci and subsequent biofilm formation and that inhibition of biofilm 
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formation can be attributed to BAR peptide delivered by NPs. 
 
The biofilm images were organized horizontally from left to right (see Figures 8 
and 9) with the NP formulation containing the highest payload of peptide (5.66 
µg/mg NP) on the left and lowest payload (1.20 µg/mg NP) on the right.  In each 
vertical columns, the molar equivalent of BAR peptide delivered by each NP 
formulation is decreased.  As shown in Figures 8 and 9, the biofilm inhibition 
increased with increasing BAR payload, even though each NP preparation 
delivered the same molar equivalent of BAR peptide.   
This suggests that BAR-NPs with higher payloads interact with P. gingivalis at 
higher valency.  In addition, as expected a dose dependent inhibition of biofilm 
formation occurred as the molar equivalent of peptide delivered by the various 
NP formulations was increased.  Table 3 summarizes the percent biofilm 
inhibition calculated for each NP formulation and for each molar equivalent of 



















Table 3   Maximum biofilm inhibition is observed for NPs functionalized with the highest 
valency of BAR peptide. Biofilm inhibition decreases as a function of NP valency and 




[BAR] µM % Inhibition 










































Figure 10 Biofilm inhibition curves showing BAR concentration versus percent inhibition 
for each NP surface modification group. Percent inhibition for 5.66 (blue), 2.90 (orange), 
1.48 (grey) and 1.20 (yellow) µg BAR/mg NP are shown.  
 
Overall, the NPs with the highest peptide valency exhibited the lowest IC50 values 
(Table 4). Conversely, as the valency of the BAR-NPs decreased, the IC50 value 
increased (Figures 10 and 11). The BAR-NPs bound to P. gingivalis significantly 
inhibited P. gingivalis-S.gordonii interaction as compared with PBS and avidin-
NPs controls (p<0.05).  
 
To determine the number of peptides corresponding to NP valency for the 
different formulations, the number of BAR peptides on each NP was calculated 
as a function of NP size, diameter, peptide MW, and conjugation density. The 
concentration of peptide conjugated per milligram NP: 5.66, 2.90, 1.48 and 1.20 
µg BAR/mg NPs (Table 2), corresponded to 2140, 1089, 556 and 451 peptides 
y = -25.128x2 + 98.143x + 2.4158
y = -18.936x2 + 77.753x + 2.7556
y = -16.605x2 + 66.795x + 2.6386


















per NP, respectively. 
 
Table 4 As the input BAR concentration decreases,the IC50 increases 







A 71 5.66 0.56 
B 35.5 2.90 0.74 
C 17.8 1.48 0.91 





                   Figure 11 The lowest IC50 is achieved in the sample 



















Input [BAR] µg/mg NPs
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Biofilm Inhibition Assay with BAR-Fc Fusion  
 
The BAR-Fc fusion biofilm inhibition assay was conducted similar to the BAR-NP 
experiment. The BAR-Fc fusion concentrations (dimer) used to determine biofilm 
inhibition were 0.25, 0.5, and 1 µM BAR-Fc. For control reactions, P. gingivalis 
was treated with defined concentrations of soluble BAR (0.5, 1.0 and 2 µM).  
Control reactions consisted of P. gingivalis incubated with Ab alone or with buffer 
alone. The biofilm images along with the controls are shown in Figure 12. In 
addition to synthesizing the dimer fusion protein, we attempted to synthesize a 
tetramer fusion protein. During the synthesis process, there were challenges in 
the expression and purification of protein. Future experiments will seek to 





Figure 12 BAR-Fc inhibition of P. gingivalis adherence to S. gordonii. Biofilms were 
visualized by confocal microscopy and image stacks were assembled using Volocity 
image analysis software. Red cells represent S. gordonii and green cells represent P. 
gingivalis. The concentrations indicated on the images represent BAR peptide equivalents 
conjugated to the antibody. 
 
Figure 12 shows that as the amount of BAR peptide is increased from 0.5 µM 
(Ab=0.25µM) to 2 µM (Ab=1µM), there is a decrease in the number of P. 
gingivalis cells (green cells) adhered to streptococci and increased inhibition of 
biofilm formation. As shown in Table 5, a dose-dependent increase in the percent 








Table 5 A BAR-Fc fusion protein containing two molar equivalents of BAR was 
synthesized and tested against free peptide for biofilm inhibition. The table shows the 
input BAR amount versus percent inhibition for increasing concentrations of peptide in 
Ab-BAR fusion proteins. Percent inhibition was calculated by quantifying fluorescence of 
the confocal images and plotted against the equimolar amounts of BAR peptide present 






A 0.5 10.77 
B 1.0 28.73 
C 2.0 63.78 
 
. 
Table 6 shows that the IC50 for the Ab-BAR fusion peptide was approximately 1.6 
µM which is similar to the IC50 of free BAR peptide. This indicates that for this 
particular formulation, the Ab-BAR fusion peptide was not more potent than 




Table 6 The IC50 of interaction for the Ab-BAR Fusion protein was determined to be 
1.61µM which is similar to that of free BAR peptide  
Peptide IC 50 
BAR 1.3 µM 
Ab-BAR Fusion 1.6 µM 







While the oral cavity accommodates both anaerobic and aerobic organisms, the 
environment of the oral cavity poses an adverse environment for organism 
survival (Dalwai et al., 2006).  Due to the action of saliva, which reduces the 
accumulation of bacteria by various mechanisms, the bacteria must struggle to 
survive and stay in the oral cavity (Dalwai et al., 2006). To counteract the effects 
of saliva, the initial colonization and adhesion of bacterial organisms to the tooth 
surface occurs via the acquired pellicle (Lindh et al., 2014). Subsequent bacterial 
adhesion and colonization occur with the help of contact-dependent signaling, 
leading to the initiation and development of polymicrobial biofilms (Donlan, 2002). 
These polymicrobial biofilms are comprised of a structured community of micro-
organisms that are adhered to the surface and enclosed in a self-generated 
matrix. Interaction within these biofilms can be mutualistic, commensalistic or 
antagonistic (Willems et al., 2016). These interactions contribute to the formation 
of subgingival biofilms that stimulate a cascade of chronic inflammatory reactions 
by the diseased tissue (Bao et al., 2014). Its initiation is attributed to the 
formation of subgingival biofilms that stimulate a cascade of chronic inflammatory 
reactions by the diseased tissue (Bao et al., 2014).  Porphyromonas
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 gingivalis, Tannerella forsythia and Treponema denticola are associated with the 
occurrence and severity of the disease and are found as a part of these biofilms 
(Bao et al., 2014). P. gingivalis is one of the ‘red’ complex bacteria and has been 
suggested to function as a keystone pathogen (Darveau et al., 2012). P. 
gingivalis can be cultivated easily and genetic tools are available to facilitate its 
study (Suzuki et al., 2013). For these reasons P. gingivalis has been extensively 
studied and is being targeted as a key organism to inhibit biofilm formation 
(Darveau et al., 2012; Suzuki et al., 2013).  Mechanistically, P. gingivalis is an 
obligate anaerobe and its primary niche is the subgingival pocket, but before it 
can establish itself there it must survive within the relative aerobic supragingival 
pocket. To enable its survival, P. gingivalis interacts with a facultative anaerobe 
S. gordonii supragingivally. This interaction is an initial event in biofilm formation, 
and represents an ideal target to inhibit the colonization of P. gingivalis and 
combat the initial stages of periodontitis. (Daep et al., 2008; Darveau et al., 2012; 
Park et al., 2005).   
The interaction between S. gordonii and P. gingivalis involves the Mfa1 of P. 
gingivalis binding to the SspB of S. gordonii (Cook et al., 1998; Daep et al., 2006; 
Park et al., 2005).  Previous studies have suggested a specific region on SspB 
that is involved in the interaction (Daep et al., 2006). This area has been 
recognized as BAR (SspB Adhering Region) and studies have led to the 
development of a peptide (BAR) which is derived from the antigen I/II protein of 
S. gordonii  ( Daep et al., 2006; Daep et al., 2008). BAR peptide has 
demonstrated potent inhibition of P. gingivalis adherence to S. gordonii.  BAR 
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also significantly reduced P. gingivalis virulence in mice which harbored S. 
gordonii and were subsequently inoculated with P. gingivalis. (Daep et al., 2011). 
Additionally, BAR peptide proved potent in a dual-species biofilm; however, its 
efficacy decreased in pre-formed and more complex biofilms, requiring increased 
quantities and longer duration of peptide incubation (Gummadi, 2013, 
unpublished). In efforts to improve potency and to achieve a concentrated dose 
of BAR at the target site, surface-modified multivalent BAR-PLGA NPs were 
constructed.  
The consideration of multivalency in the design of therapeutic carriers has the 
potential to enhance the inhibitory potential of low affinity molecules by 
increasing the number of interactions and decreasing the dissociation rates 
(avidity), between the delivery carrier and its therapeutic binding target. 
(Chittasupho, 2012). Multivalent approaches have proven effective to block the 
attachment of the influenza virus to its target cell by an inhibitor which is 
multivalent (Mammen et al, 1998). Similarly, multivalent targeting approaches 
amplified angiotensin II receptor type 1 blockade in the eye and concomitantly 
deliver a therapeutic payload into ocular lesions. In this project we implemented 
the concepts of multivalency to create high avidity interactions between the BAR-
modified NPs and the bacterial binding receptors. We hypothesized that carriers 
with increased valency would increase the potency of the peptide (Chittasupho, 
2012).  
 
Nanoparticle technology has contributed to a variety of translational applications, 
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demonstrating versatility and biocompatibility in the delivery of an assortment of 
cargo, including drugs, genes, and proteins. Recently, NPs have found use in 
various areas of restorative dentistry, minimally invasive dental procedures, 
cancer diagnosis and treatment, molecular imaging and implant dentistry (Mantri 
& Mantri, 2013). Due to their high structural integrity, stability during storage, 
ease of preparation and functionalization, and controlled release capability, 
polymeric NPs are highly attractive as drug delivery vehicles (Cheow & Hadinoto, 
2014).  
Recent studies employing NPs for oral applications, have shown that BAR-NPs 
are more potent than the soluble BAR in inhibiting P. gingivalis adherence to S. 
gordonii, and preventing biofilm formation (Steinbach-Rankins, Demuth, 
unpublished).  In this work, NPs were surface-modified with avidin to bind to the 
biotin of the BAR peptide. Avidin-biotin-ligand conjugation is considered to be 
one of the strongest non-covalent bonds and offers an efficient method of 
attaching the peptide to the NP surface (Bratthauer, 2010; Howarth et al., 2006). 
It was determined that each avidin has four biotin binding sites, but due to their 
close proximity to each other, leading to steric hindrance, we assumed that only 
two of the biotin-binding sites were available for biotinylated BAR conjugation 
(Howarth et al., 2006; Steinbach et al., 2016). The mechanism by which the 
PLGA-NPs enhanced the potency of the BAR peptide may be due to increased 
localized concentration of the BAR peptide or by promoting a multivalent binding 
interface to increase the avidity of BAR with P. gingivalis. In our experiments we 
hypothesized that BAR-NPs increased the avidity of the interaction by increasing 
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the valency of BAR, thereby increasing the potency relative to free BAR peptide. 
We used two experimental assays to evaluate the efficacy as a function of 
increased BAR valency. Biofilm inhibition assays were performed using BAR-
NPs and BAR-Fc fusion proteins, and the percent inhibition of P. gingivalis to S. 
gordonii adherence was compared to that of free BAR peptide.  
First a direct approach was used to quantify the amount of BAR bound to the NP 
surface. BAR-Flc was reacted with NPs at concentrations of: 8.9, 17.8, 35.5, 71, 
142, and 284 µg BAR/mg NPs. We varied these concentrations around a three-
fold molar excess of BAR (71µg BAR/mg NPs) to available binding sites and 
observed that at this concentration, all available avidin binding sites were 
saturated on the NP surface. The percentage of BAR bound to the NPs, relative 
to the input concentration remained constant (24%) even upon increased 
concentrations of reactant BAR (e.g. 142 and 284 µg BAR/mg NPs). In 
comparison with previous experiments, in which the same amount of avidin was 
added to 100 mg versus 50 mg PLGA NPs, half the amount of BAR was needed 
(71 vs. 142 µg) indicating that less avidin may be used during the synthesis 
process to induce similar binding results. In our experiments, we achieved 1.20 ± 
0.68, 1.48 ± 0.17, 2.90 ± 0.16, and 5.66 ± 0.20 µg BAR/mg NPs, bound to the NP 
surface at input concentrations of 8.9, 17.8, 35.5, and 71 µg BAR/mg NPs, 
respectively, demonstrating very efficient binding. 
To determine if this increase in the binding efficiency was attributed to an 
increase in valency, similar concentrations of BAR-NPs (8.9, 17.8, 35.5, 71, 142, 
and 284 µg BAR/mg NPs) were reacted with P. gingivalis.  P. gingivalis cells 
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were subsequently incubated with immobilized S. gordonii to form biofilms. Five 
different equimolar BAR peptide concentrations (0.3, 0.7, 1.3, 2.0, and 2.5 µM) 
for each batch of BAR-NPs (with differing valency) were evaluated. As the 
equimolar BAR NP concentration increased, biofilms were increasingly inhibited 
and P. gingivalis to S. gordonii interaction decreased. We also found out that the 
50% inhibitory concentration was highest for the BAR-NP sample that had the 
maximum BAR density (valency) on the NP surface.  
Next, we used a different platform to deliver BAR peptide – a BAR -Ab fusion 
protein. IgG was used in a dimer form and BAR peptide was fused to it using a 
novel plant based production platform, with one molecule of antibody carrying 
two molecules of BAR (Hamorsky et al., 2013). The biofilms were formed using a 
concentration range of BAR: 0.5 µM (Ab=0.25µM), 1 µM (Ab=0.5 µM), and 2 µM 
(Ab=1µM), and biofilm inhibition was quantified. Although a linear increase in the 
percent inhibition was observed as the amount of BAR peptide increased, the 
IC50 (1.6 M) was similar to that of free BAR alone (IC50=1.3µM). Hence, to make 
the BAR-Fc fusion more potent, we believe that more BAR molecules need to be 
fused per Ab molecule. As we calculated before, 451 molecules of BAR are 
present per NP in 8.9 µg BAR/mg NP (lowest valency) batch as compared to 2 
molecules in a BAR-Fc fusion, it is not surprising that we did not see an increase 
in potency of BAR in BAR-Fc fusion proteins. Our data, therefore, suggests that 
increased number of BAR molecules are required to improve the fusion protein 
potency. We also speculate that if the tetramer form of BAR-Fc fusion (Fc’) were 
to be tested, we would not have been able to observe an increase in the potency 
 48
of that particular formulation as we believe that more than 2 but less than 451 
molecules of BAR are required to achieve the desired effect. This comparison 
highlights differences between platforms that enable low, relative to high density 
modification; however, we acknowledge that there are likely differences in 
available BAR spatial arrangements between NP and Ab carriers. Therefore, 
even equivalent amounts of BAR on each carrier may exhibit dissimilar effects in 
binding, due to platform differences. 
This concept of the increased percent inhibition due to an increase in valency, 
provides us a solid framework to develop therapeutics, by designing NPs to 
specifically target microorganisms more effectively and safely. As recent studies 
suggest that P. gingivalis plays a significant role in altering the host-microbe 
homeostasis, new delivery platforms for BAR peptide seek to block P. gingivalis 
interactions more effectively. We understand that the etiology of periodontitis is 
very complex and there might be many more bacterial interactions 
simultaneously involved, which might have significant impact on disease 
progression. The surface-modified NPs could, therefore, be applied to target 
other bacterial interactions in the oral cavity and combat the bacterial 
colonization, thereby, periodontitis. This could be achieved by modifying the NPs 
with peptides pertaining to particular interactions.  
The experimental results suggest that by increasing NP valency, we can obtain 
increased avidity and potency of the peptide. This paves the way for lower 
concentrations of BAR to be used, while still achieving similar efficacy. Constant 
flow of saliva in the oral cavity and the intake of food and water may regularly 
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wash out the therapeutic peptides (BAR) which would decrease the effectiveness 
of BAR. Due to the efficacy of BAR-NPs at both high and low concentrations, 
relative to free BAR peptide, this approach may prove very beneficial. Since BAR 
peptide is relatively expensive to produce, this method of conjugating BAR to 
NPs may offer a more cost effective alternative for delivery. Additionally, because 
of the conjugation with NPs, BAR can be delivered locally in a concentrated form 
to increase BAR effectiveness. For translational applications, BAR-modified NPs 
may, eventually, be prescribed as mouthwashes or chewing gums after oral 
prophylaxis procedures done in a dental office. This would offer a cure for 
periodontitis and not just a preventive treatment like scaling or gingival surgery.  
 
We are still establishing effect of BAR-modified NPs on pre-formed and more 
complex biofilms. Future directions of this research project will study the effect of 
BAR-NPs in established biofilms as well as in more complex biofilms with 
Fusobacterium nucleatum, in vitro. From a design perspective, decreased avidin 
reactant may be used for conjugation to the NP surface, which may further 
increase the potency of the BAR peptide. Experiments will also be conducted to 
determine the toxicity of surface-modified NPs in human gingival cells, with 
eventual translation to animal models. Regarding BAR-Fc fusion proteins, 
additional modifications of the non-Fc binding BAR Abs will be pursued to 
enhance their therapeutic potential. For example, they may be constructed in 
tetramer or higher valency forms, which would incorporate four or more 
molecules for BAR per molecule of Ab. These formulations may prove promising 
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for inhibition. To benefit from both delivery technologies, we may investigate Ab-
BAR-NPs, to enhance and prolong effects in the oral cavity. Our long-term goal is 
to develop a therapeutic that can be approved to be tested in clinical trials. We 
envision that clinical trials will require recognizing that the oral cavity is a niche 
for many organisms. This would involve creating conditions that would harbor 
only the bacteria that need to be studied. We envision that clinical prevention and 
treatment may involve the administration of BAR peptide immediately after oral 
prophylaxis. With this, the number of P. gingivalis cells that recolonize the oral 
cavity with time can be used as an outcome to assess the efficacy of BAR-NP 
preparations.  For example, one possible approach is to subject patients to oral 
prophylaxis and then provide one group with a mouth rinse containing BAR-NPs 
and a second group with a placebo formulation.  The kinetics of P. gingivalis 
recolonization would serve as the outcome to determine the effectiveness of the 
treatment protocol.  In these experiments, patient compliance must be monitored 
very carefully. Overall, BAR-NPs look very promising and may pave the way to 
develop therapeutics that would actually prevent biofilms from forming and 
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